"All currently available OACs increase the risk of bleeding. In the management of VTE, a significant proportion of patients are recommended long-term OAC, meaning that cumulative risk can be ...
The researchers found that the incidence of VTE was 11.0 versus 12.9 events per 1,000 patient-years in the GLP-1 RA and DPP-4 inhibitor cohorts, respectively, with an 18% lower risk for VTE for ...